Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Elneil, Sohier; Lalezari, Jacob; Pourhassan, Nader

doi:10.1016/j.jtauto.2021.100097

Search citation statements

Order By: Relevance

Paper Sections

Select...

Sars-cov-2 and Conventional Igg Mabs1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 98 Emapalumab Human IgG1 - IFN-γ - Phase 2/3 (NCT04324021) 99 Leronlimab (PRO 140) Humanized IgG4κ Mouse CCR5 - Phase 2/3 (NCT04343651, etc.) 100 Complement Ravulizumab Humanized IgG2 Mus musculus C5 - Phase 3/4 (NCT04570397, etc.) 101 Eculizumab Humanized IgG2/4κ Mouse C5 - Phase 2/3 (NCT04288713, etc.)…”

Section: Sars-cov-2 and Conventional Igg Mabsmentioning

confidence: 99%

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Zhang

Sun

2022

mAbs

View full text Add to dashboard Cite

Early humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus neutralization at mucosal sites. Given the essential roles of IgM and IgA in the control and elimination of SARS-CoV-2 infection, the mucosal immunity could be exploited for therapeutic and prophylactic purposes. However, almost all neutralizing antibodies that are authorized for emergency use and under clinical development are IgG antibodies, and no vaccine has been developed to boost mucosal immunity for SARS-CoV-2 infection. In addition to IgM and IgA, bispecific antibodies (bsAbs) combine specificities of two antibodies in one molecule, representing an important alternative to monoclonal antibody cocktails. Here, we summarize the latest advances in studies on IgM, IgA and bsAbs against SARS-CoV-2. The current challenges and future directions in vaccine design and antibody-based therapeutics are also discussed.

show abstract